Result snapshot (Rs.mn) | Q3FY24 | Q3FY23 | YoY (%) | Q2FY24 | QoQ (%) | CEBPL EST. Dev. (%) | Dev. (%) |
---|---|---|---|---|---|---|---|
Volume | 2,28,073 | 2,21,401 | 3.0 | 2,29,280 | (0.5) | 2,28,284 | (0.1) |
Net ASP (Rs/veh) | 1,83,224 | 1,68,066 | 9.0 | 1,79,454 | 2.1 | 1,75,942 | 4.14 |
Net sales (incl 001) | 41,788 | 37,210 | 12.3 | 41,145 | 1.6 | 40,165 | 4.0 |
Material Exp. | 22,579 | 21,655 | 4.3 | 22,201 | 1.7 | 22,291 | |
Employee Exp. | 3,093 | 2,594 | 19.3 | 3,061 | 1.1 | 2,932 | |
Other Operating Exp. | 5,214 | 4,389 | 18.8 | 5,012 | 4.0 | 4,458 | |
EBITDA | 10,903 | 8,572 | 27.2 | 10,872 | 0.3 | 10,483 | 4.0 |
EBIDTA/ (Rs./Veh) | 47,804 | 38,718 | 23.5 | 47,416 | 0.8 | 45,921 | 4.1 |
PBT | 11,840 | 9,071 | 30.5 | 12,057 | (1.8) | 11,365 | |
EOI - Gain / (Loss) | - | - | ΝΑ | - | NA | - | |
Share of JV | 1,139 | 639 | 78.2 | 1,016 | 12.0 | 1,020 | 11.7 |
RPAT | 9,960 | 7,408 | 34.4 | 10,163 | (2.0) | 9,430 | 5.6 |
APAT | 9,960 | 7,408 | 34.4 | 10,163 | (2.0) | 9,430 | 5.6 |
Adj EPS (Rs.) | 36.4 | 27.1 | 34.4 | 37.2 | (2.0) | 34.5 |
Operational performance | Q3FY24 | Q3FY23 | YoY (bps) | Q2FY24 | QoQ (bps) | CEBPL EST. | Dev. (bps) |
---|---|---|---|---|---|---|---|
Gross margin (%) | 46.0 | 41.8 | 417 | 46.0 | (7) | 44.5 | 146.8 |
EBITDA margin (%) | 26.1 | 23.0 | 305 | 26.4 | (33) | 26.1 | (1.0) |
Employee Exp. % of Sales | 7.4 | 7.0 | 43 | 7.4 | (4) | 7.3 | 10.2 |
Other Operating Exp. % Net Sales | 12 | 12 | 68 | 12 | 30 | 11 | 137.6 |
APAT margin (%) | 23.8 | 19.9 | 392 | 24.7 | (87) | 23.5 | 35.6 |
Source: Company, CEBPL
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.